Biphasic Mesothelioma
Biphasic mesothelioma contains both epithelioid and sarcomatoid cells, found in 20-30% of cases. Prognosis depends on which cell type dominates the tumor ratio.
Overview
Biphasic tumors contain a mix of epithelioid and sarcomatoid cells. Your prognosis depends on the ratio. More epithelioid cells mean better treatment options and longer survival times.
Characteristics
- Contains both epithelioid and sarcomatoid cells
- Must have at least 10% of each cell type
- Cell types may be intermixed or in separate regions
- Behavior varies based on dominant cell type
- Prognosis correlates with epithelioid percentage
- Requires careful pathological examination
Subtypes
Epithelioid-dominant
More than 50% epithelioid cells; better prognosis
Sarcomatoid-dominant
More than 50% sarcomatoid cells; poorer prognosis
Balanced
Roughly equal proportions; intermediate prognosis
Diagnosis
Accurate cell type identification is critical for treatment planning. Diagnosis typically involves:
- Large tissue sample needed to identify both cell types
- Pathologist must examine multiple tumor sections
- Immunohistochemistry helps identify each component
- Cell type ratio should be documented
- Small biopsies may miss one cell type
Treatment Options
Treatment for biphasic mesothelioma may include:
- Treatment approach depends on dominant cell type
- Surgery may be considered if epithelioid-dominant
- Chemotherapy response varies by cell composition
- Immunotherapy may benefit some patients
- Treatment plan individualized based on pathology
Prognosis
If your tumor is mostly epithelioid (over 50%), your prognosis is closer to pure epithelioid cases. Surgery and aggressive treatment may be worthwhile. Higher sarcomatoid content means a tougher road.
Learn about mesothelioma prognosis factors →Getting a Second Opinion
Because cell type significantly affects treatment options and prognosis, obtaining a second opinion on your pathology results from a mesothelioma specialist is often recommended. Pathologists with mesothelioma experience are more likely to accurately identify cell type, subtypes, and any unusual features that may affect your treatment plan.
Cell Type Q&A
Frequently Asked Questions
What is the prognosis for biphasic mesothelioma?
Biphasic mesothelioma generally carries a poorer prognosis than purely epithelioid disease, with most large series reporting a median survival of about 9 to 11 months after diagnosis. Data from databases and cohort studies describe an average life expectancy around 10 months, 2‑year survival near 22%, and 5‑year survival near 5%. Outcomes vary widely based on the ratio of epithelioid to sarcomatoid cells, tumor location (pleural or peritoneal), stage at diagnosis, overall health, and access to multimodal treatment such as surgery, chemotherapy, and immunotherapy. Some reports document people with biphasic mesothelioma living 3 years or longer, and occasionally 5 to 7 years, particularly when tumors are predominantly epithelioid and treated aggressively.
How do you treat biphasic mesothelioma?
People with biphasic mesothelioma receive treatments including immunotherapy with nivolumab plus ipilimumab as a first-line option for pleural cases, chemotherapy such as pemetrexed with cisplatin, surgery like pleurectomy with decortication or cytoreduction with HIPEC for peritoneal disease, and radiation. Multimodal approaches combining these therapies show responses in case reports, with one biphasic pleural case achieving no recurrence 11 months after chemotherapy and surgery. Immunotherapy extends survival beyond 20 months in some previously treated pleural patients, while chemotherapy alone yields about 12-month median survival and 17% 3-year rates per NCDB data. Emerging options like pegargiminase with chemotherapy target sarcomatoid components in biphasic tumors. Treatment selection depends on cell ratio, stage, location, and health.
How did Steve McQueen get mesothelioma?
Steve McQueen was exposed to asbestos through multiple occupational and military sources over several decades. His primary exposure occurred during his service in the U.S. Marine Corps from 1947 to 1950, when he worked aboard naval ships and in shipyards, including removing asbestos lagging from pipes at Camp Lejeune. After his military service, he encountered additional asbestos exposure on movie soundstages where insulation contained the mineral, while wearing flame-resistant racing suits made with asbestos, and while working on race car and motorcycle brakes. McQueen did not develop symptoms until 1978, nearly 30 years after his initial military exposure, reflecting the typical latency period of 20 to 50 years between asbestos exposure and mesothelioma diagnosis. He was diagnosed with pleural mesothelioma in December 1979 and died in November 1980 at age 50.
What is a biphasic mesothelioma pattern?
Biphasic mesothelioma contains both epithelioid and sarcomatoid cells, with a diagnosis requiring at least 10% of each cell type in tumor tissue examined via biopsy. Epithelioid cells are cube-shaped or elongated and form structured patterns, while sarcomatoid cells are spindle-shaped, tightly packed, and more aggressive. This subtype accounts for 20-35% of malignant pleural mesothelioma cases and behaves based on the ratio of the two cell types, with higher sarcomatoid content linked to faster spread. It most often occurs in the pleura but can appear in the peritoneum, pericardium, or tunica vaginalis.